scholarly journals Prognostic Value of Bone Marrow Micrometastasis in Patients with Operable Esophageal Squamous Cell Carcinoma: A Long-Term Follow-Up Study

2014 ◽  
Vol 9 (8) ◽  
pp. 1207-1213 ◽  
Author(s):  
Shao-bin Chen ◽  
Xiao-dong Su ◽  
Guo-wei Ma ◽  
Peng Lin ◽  
Jing Wen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Prognostic Value ◽  
Follow Up Study ◽  
Bone Marrow Micrometastasis ◽  
Long Term Follow Up

Long-term Follow-up after Complete Ablation of Early Esophageal Squamous Cell Carcinoma with Argon Plasma Coagulation

2014 ◽  
Vol 65 (4) ◽  
pp. 314-321
Author(s):  
Kenro Kawada ◽  
Tatsuyuki Kawano ◽  
Yasuaki Nakajima ◽  
Toshihiro Matsui ◽  
Masafumi Okuda ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Argon Plasma Coagulation ◽  
Argon Plasma ◽  
Plasma Coagulation ◽  
Long Term Follow Up

Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study

2012 ◽  
Vol 20 (6) ◽  
pp. 1865-1871 ◽  
Author(s):  
Christoph Domschke ◽  
Ingo J. Diel ◽  
Stefan Englert ◽  
Silvia Kalteisen ◽  
Luisa Mayer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Primary Breast Cancer ◽  
Prognostic Value ◽  
Disseminated Tumor Cells ◽  
Follow Up Study ◽  
Long Term Follow Up

733: The Prognostic Value of E-Cadherin, Alpha-, and Beta-Catenin in Invasive Bladder Cancer Patients: Long Term Follow-Up Study

2004 ◽  
Vol 171 (4S) ◽  
pp. 194-195
Author(s):  
Kyoichi Tomita ◽  
Haruki Kume ◽  
Keishi Kashibuchi ◽  
Satoru Muto ◽  
Shigeo Horie ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Invasive Bladder Cancer ◽  
Beta Catenin ◽  
Follow Up Study ◽  
Long Term Follow Up ◽  
E Cadherin

Lack of Prognostic Value of Normalized Integrated Backscatter Analysis of Myocardium in Patients with Thalassemia Major: A Long-Term Follow-Up Study

2005 ◽  
Vol 22 (3) ◽  
pp. 239-244 ◽  
Author(s):  
Zoltan Jambrik ◽  
Giorgio Derchi ◽  
Eugenio Picano ◽  
Lamia Ait-Ali ◽  
Gianluca Forni ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Thalassemia Major ◽  
Integrated Backscatter ◽  
Follow Up Study ◽  
Long Term Follow Up

Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 207-207
Author(s):  
Ken Kato ◽  
Yuichiro Doki ◽  
Takashi Ura ◽  
Yasuo Hamamoto ◽  
Takashi Kojima ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Squamous Cell ◽  
Group Performance ◽  
Objective Response

207 Background:ATTRACTION-1/ONO-4538-07 (AT-1), an open-label, single-arm, multicenter phase 2 clinical trial conducted in Japan, evaluated the clinical activity and safety of nivolumab in patients with advanced esophageal squamous cell carcinoma (ESCC) refractory/intolerant to fluoropyrimidine-, platinum-, and taxane-based chemotherapy. We previously reported the 2-year follow-up findings of AT-1, in which nivolumab demonstrated antitumor activity with a manageable safety profile for these patients. Here we report the final findings from AT-1 at a minimum follow-up of 5 years. Methods:Patients aged ≥20 years with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1 received 3 mg/kg nivolumab intravenously every 2 weeks in 6-week cycles until disease progression or unacceptable toxicity. The primary endpoint was centrally-assessed objective response rate (ORR), defined as the proportion of patients whose best overall response was either a complete or partial response. Secondary endpoints included overall survival (OS), investigator-assessed ORR, progression-free survival (PFS), change in tumor burden, time to response, time to disease progression, and duration of response. Results:Between February 25 and November 14, 2014, a total of 65 patients were enrolled. Sixty-four patients were evaluated for the efficacy, and all patients were evaluated for the safety. At the final database lock on August 6, 2020, 11 (17.2%, 95% confidence interval [CI] 9.9-28.2) of 64 patients had an objective response by central assessment. The median OS was 10.8 months (95% CI, 7.4-13.9), and the estimated 5-year OS rate was 6.3% (95% CI, 2.0-14.0). The median PFS was 1.5 months (95% CI, 1.4-2.8), and the estimated 5-year PFS rate was 6.8% (95% CI, 2.2-15.1). Treatment-related adverse events that occurred with a frequency of > 10% were diarrhea and rash. The presentation will include characteristics of long-term survivors as well as detailed efficacy and safety data of nivolumab. Conclusions:This final assessment represents the longest follow-up of patients with advanced ESCC treated with nivolumab. Nivolumab demonstrated continued long-term efficacy in these patients based on a minimum of 5-year long-term survival update of AT-1. Furthermore, no new safety signals with nivolumab were identified during long-term follow-up. These findings are consistent with those of nivolumab monotherapy for various types of cancer. Clinical trial information: No.142422.

Sign in / Sign up

Export Citation Format

Share Document